ENDRA Files S-1/A for Continuous Offering, Signaling Capital Raise

TL;DR

**NDRA is raising cash, expect dilution but it's a necessary move for this small cap to survive and innovate.**

AI Summary

ENDRA Life Sciences Inc. (NDRA) filed an S-1/A on July 25, 2025, for a delayed or continuous offering of securities, indicating a capital raise strategy rather than immediate operational changes. The filing does not disclose specific revenue or net income figures, but its status as a 'non-accelerated filer' and 'smaller reporting company' suggests it has not yet achieved significant financial scale. Key business changes are not detailed in this amendment, which primarily focuses on the registration of securities under Rule 415 of the Securities Act of 1933. The strategic outlook appears to be centered on securing additional funding to support its operations and product development, likely for its electromedical and electrotherapeutic apparatus. Risks include the inherent uncertainties of a continuous offering and the potential dilution for existing shareholders, though specific risk factors are not enumerated in the provided excerpt. The company's primary business address is 3600 Green Court, Suite 350, Ann Arbor, MI 48105.

Why It Matters

This S-1/A filing signals ENDRA Life Sciences' intent to raise capital through a continuous offering, which is crucial for its ongoing operations and product development in the competitive electromedical device market. For investors, it means potential dilution from new share issuances, but also a lifeline for a smaller reporting company. Employees and customers might see this as a positive step towards securing the company's future, enabling continued innovation in its specialized apparatus. The broader market will watch how NDRA leverages this capital to compete against larger, more established medical device manufacturers.

Risk Assessment

Risk Level: high — The risk level is high because the S-1/A indicates a 'delayed or continuous basis' offering, which often leads to significant shareholder dilution. As a 'smaller reporting company' and 'non-accelerated filer,' ENDRA likely faces challenges in securing capital, and a continuous offering can depress share prices over time. The lack of specific financial performance data in the excerpt further heightens uncertainty.

Analyst Insight

Investors should exercise caution and thoroughly research ENDRA's financial health and product pipeline before considering an investment. Monitor the timing and size of any future offerings, as significant dilution could negatively impact current share value. This filing is a signal for potential future capital raises, not an immediate investment opportunity.

Executive Compensation

Key Numbers

• 333-288575 — Registration No. (SEC file number for the S-1/A filing)
• 2025-07-25 — Filing Date (Date the S-1/A was filed with the SEC)
• 3845 — SIC Code (Standard Industrial Classification for Electromedical & Electrotherapeutic Apparatus)
• 26-0579295 — IRS Employer Identification Number (EIN for ENDRA Life Sciences Inc.)
• 1933 Act — SEC Act (Securities Act under which the S-1/A is filed)

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — Registrant for S-1/A filing
• Alexander Tokman (person) — Chief Executive Officer of ENDRA Life Sciences Inc.
• Mark R. Busch, Esq. (person) — Counsel at K&L Gates LLP
• Coleman Wombwell, Esq. (person) — Counsel at K&L Gates LLP
• K&L Gates LLP (company) — Law firm providing copies to counsel
• Robert Charron, Esq. (person) — Counsel at Ellenoff Grossman & Schole LLP
• Ellenoff Grossman & Schole LLP (company) — Law firm providing copies to counsel
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• 3600 Green Court, Suite 350, Ann Arbor, MI 48105-1570 (company) — Principal executive offices of ENDRA Life Sciences Inc.
• 734-335-0468 (dollar_amount) — Business phone number of ENDRA Life Sciences Inc.

FAQ

Industry Context

ENDRA Life Sciences operates within the Electromedical & Electrotherapeutic Apparatus industry (SIC Code 3845). This sector is characterized by innovation in medical imaging and therapeutic devices, often requiring significant R&D investment and facing stringent regulatory approvals. Competition can be intense, with established players and emerging companies vying for market share.

Regulatory Implications

As a non-accelerated filer and smaller reporting company, ENDRA Life Sciences benefits from scaled disclosure requirements. However, the continuous offering under Rule 415 implies ongoing SEC oversight and the need to maintain updated registration statements. Any future product development or commercialization will be subject to FDA regulations and other healthcare industry compliance standards.

What Investors Should Do

1. Review prior S-1 filings for detailed financial statements and risk factors.
2. Monitor future filings for updates on the continuous offering and capital deployment.
3. Assess the company's product development pipeline and market adoption strategy.

Key Dates

• 2025-07-25: Filing of S-1/A Amendment No. 2 — Indicates the company is continuing its strategy to raise capital through a delayed or continuous offering of securities.
• 2016-08-05: Name Change from Endra Inc. — Marks a formal change in the company's corporate identity.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC, used to update or correct information previously submitted. (This filing indicates ENDRA Life Sciences is amending its initial registration statement, likely to provide updated information or to continue its offering.)

Rule 415

A rule under the Securities Act of 1933 that permits companies to register securities for a continuous or delayed offering. (The company is utilizing Rule 415, signaling its intention to raise capital over time rather than in a single, immediate offering.)

Non-accelerated filer

A filer that does not meet the thresholds for accelerated or large accelerated filer status, generally indicating a smaller company size. (This classification suggests ENDRA Life Sciences is a smaller company with less than $75 million in public float, impacting its reporting requirements.)

Smaller reporting company

A company that meets certain criteria regarding public float and revenue, allowing for scaled disclosure requirements. (This designation, along with 'non-accelerated filer', reinforces the company's smaller financial scale and reduced disclosure burden.)

SIC Code 3845

Standard Industrial Classification code for Electromedical & Electrotherapeutic Apparatus. (This code categorizes ENDRA Life Sciences' primary business activity, placing it within the medical device sector focused on electrical apparatus.)

Year-Over-Year Comparison

This filing is an amendment (S-1/A) to a registration statement, not a periodic report like a 10-K or 10-Q. Therefore, direct year-over-year comparisons of financial metrics such as revenue, net income, or margins are not possible from this document alone. The filing's primary purpose is to register securities for a continuous offering, indicating a strategy to secure ongoing funding rather than reporting on past performance.

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on July 25, 2025 by Alexander Tokman regarding ENDRA Life Sciences Inc. (NDRA).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR